Based on both network 1 and network 2, it was manifested that all currently available EGFR-TKIs were comparable in terms of ORR, PFS and OS (with only erlotinib, gefitinib and afatinib were compared for OS data) as treatments for EGFR mutated NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.